MCID: WGN006
MIFTS: 62

Wegener Granulomatosis malady

Categories: Rare diseases, Neuronal diseases, Cardiovascular diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Immune diseases, Skin diseases

Aliases & Classifications for Wegener Granulomatosis

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 25Genetics Home Reference, 29ICD10, 30ICD10 via Orphanet, 31ICD9CM, 37MedlinePlus, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 49Novoseek, 51OMIM, 53Orphanet, 61SNOMED-CT, 67UMLS, 68UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Wegener Granulomatosis:

Name: Wegener Granulomatosis 51 11 47 25 53 12
Granulomatosis with Polyangiitis 47 25 53 37 38 67
Wegener's Granulomatosis 11 25 13
Gpa 47 25 53
Midline Granulomatosis 47 67
Pauci-Immune Glomerulonephritis Associated with Granulomatosis with Polyangiitis 67
 
Necrotizing Respiratory Granulomatosis 11
Granulomatosis - Wegener's 11
Wegeners Granulomatosis 49
Wegener's Syndrome 11
Wg 47

Characteristics:

Orphanet epidemiological data:

53
granulomatosis with polyangiitis:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-5/10000 (Sweden),1-9/1000000 (Germany),1-9/100000 (France),1-9/100000 (Sweden),1-9/100000 (Norway),1-9/100000 (Australia),1-9/100000 (New Zealand),1-9/100000 (United States),1-9/100000 (China),1-9/1000000 (Lithuania),1-9/1000000 (Greece),1-9/1000000 (Italy),1-9/1000000 (Canada),1-9/1000000 (Japan),<1/1000000 (Taiwan, Province of China),1-9/100000 (Italy),1-5/10000 (Denmark); Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

OMIM51 608710
Disease Ontology11 DOID:12132
ICD1029 M31.3, M31.30
ICD9CM31 446.4
MeSH38 D014890
NCIt44 C3444
Orphanet53 ORPHA900
MESH via Orphanet39 D014890
UMLS via Orphanet68 C0043092
ICD10 via Orphanet30 M31.3

Summaries for Wegener Granulomatosis

About this section
MedlinePlus:37 Granulomatosis with polyangiitis (gpa), previously known as wegener's granulomatosis, is a rare disease. it is a type of vasculitis, or inflammation of the blood vessels. the inflammation limits the flow of blood to important organs, causing damage. it can affect any organ, but it mainly affects the sinuses, nose, trachea (windpipe), lungs, and kidneys. the cause of gpa is unknown. it can affect people at any age. men and women are equally affected. it is more common in whites. symptoms may include joint pain, weakness, tiredness, and cold symptoms such as a runny nose that doesn't get better. doctors use blood tests, chest x-rays, and biopsies to diagnose gpa and rule out other causes of the symptoms. early treatment is important. most people improve with medicines to slow or stop the inflammation. nih: national institute of allergy and infectious diseases

MalaCards based summary: Wegener Granulomatosis, also known as granulomatosis with polyangiitis, is related to asthma and goodpasture syndrome, and has symptoms including abnormality of the oral cavity, sinusitis and epistaxis. An important gene associated with Wegener Granulomatosis is WG (Wegener Granulomatosis), and among its related pathways are C-MYB transcription factor network and amb2 Integrin signaling. The drug cyclophosphamide has been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and skin, and related mouse phenotypes are cardiovascular system and liver/biliary system.

Disease Ontology:11 An autoimmune disease that is located in lung, located in kidney, located in skin resulting from an autoimmune attack by antineutrophil cytoplasmic antibodies against small and medium-size blood vessels.

Genetics Home Reference:25 Granulomatosis with polyangiitis (GPA) is a condition that causes inflammation that primarily affects the respiratory tract (including the lungs and airways) and the kidneys. This disorder is also commonly known as Wegener granulomatosis. A characteristic feature of GPA is inflammation of blood vessels (vasculitis), particularly the small- and medium-sized blood vessels in the lungs, nose, sinuses, windpipe, and kidneys, although vessels in any organ can be involved. Polyangiitis refers to the inflammation of multiple types of vessels, such as small arteries and veins. Vasculitis causes scarring and tissue death in the vessels and impedes blood flow to tissues and organs.

OMIM:51 Wegener granulomatosis (WG) is a systemic disease with a complex genetic background. It is characterized by necrotizing... (608710) more...

NIH Rare Diseases:47 Granulomatosis with polyangiitis (Wegener's) is a type of vasculitis, or inflammation of the blood vessels. This limits the flow of blood to important organs, causing damage. It can affect any organ, but it mainly affects the sinuses, nose, trachea (windpipe), lungs and kidneys. Symptoms can vary in nature and severity, and may include sinus pain; discolored or bloody fluid from the nose; nasal ulcers; constant runny nose (rhinorrhea); joint pain; weakness; tiredness; and/or skin lesions. The cause of granulomatosis with polyangiitis is unknown. Early treatment is important. Most people improve with medicines to slow or stop the inflammation. Last updated: 5/25/2015

Wikipedia:70 Granulomatosis with polyangiitis (GPA), previously known as Wegener\'s granulomatosis (WG), is a... more...

Related Diseases for Wegener Granulomatosis

About this section

Diseases related to Wegener Granulomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 185)
idRelated DiseaseScoreTop Affiliating Genes
1asthma29.8ELANE, HLA-DPB1, IFNG, MPO, SELE, TNF
2goodpasture syndrome29.5CCR5, CD8A, CRP, CTLA4, IFNG, SELE
3rheumatoid arthritis29.4CD80, CRP, CTLA4, HLA-DPB1, IFNG, PRTN3
4eosinophilic granulomatosis with polyangiitis12.5
5hepatocellular adenoma10.8CRP, MPO, PRTN3
6acute porphyria10.8CRP, MPO, TNF
7acute cholangitis10.8CRP, MPO, TNF
8panner disease10.8CRP, IFNG, TNF
9linitis plastica10.8CD8A, TNF
10intestinal variant cervical mucinous adenocarcinoma10.8CRP, MPO, TNF
11weber syndrome10.8MPO, TNF
12arteriosclerosis10.7MPO, PRTN3
13hemophagocytic lymphohistiocytosis10.7CTLA4, IFNG, TNF
14jumping frenchmen of maine10.7CD177, CRP, TNF
15baetz-greenwalt syndrome10.7IFNG, TNF
16chromoblastomycosis10.7CRP, MPO, SELE
17parsonage turner syndrome10.7HLA-DPB1, TNF
18motor peripheral neuropathy10.7IFNG, MPO
19bone cancer10.7CRP, MPO
20binocular vision disease10.7CTLA4, IFNG, TNF
21cerebral atrophy10.7ELN, MPO, TNF
22antigen-peptide-transporter 2 deficiency10.7CTLA4, PTPN22, TNF
23nervous system cancer10.7CTSG, ELANE, TNF
24autoimmune pancreatitis10.7IFNG, TNF
25lipid storage disease10.7CRP, PRTN3, TNF
26stromal predominant kidney wilms' tumor10.7CRP, MPO
27discitis10.7MPO, SELE, TNF
28gonococcal synovitis10.7IFNG, SELE, TNF
29esophagus melanoma10.7CRP, IFNG, TNF
30gastric ulcer10.7CTLA4, IFNG, TNF
31cutaneous porphyria10.7CRP, IFNG, TNF
32spondylolysis10.7CRP, IFNG, TNF
33primary orthostatic tremor10.7CCR5, IFNG, TNF
34proliferative glomerulonephritis10.7CRP, ELANE, MPO, PRTN3
35cryoglobulinemia10.7CRP, MPO, TNF
36calcifying epithelial odontogenic tumor10.7CTLA4, IFNG, SELE
37bartter disease10.7CTLA4, IFNG, TNF
38conventional leiomyosarcoma10.7CD8A, CRP, MPO
39complex partial epilepsy10.7CD8A, ELANE, MPO
40leukostasis10.7IFNG, SELE, TNF
41inner ear disease10.7CRP, IFNG, TNF
42sensorineural hearing loss10.7CCR5, IFNG, TNF
43dementia - subcortical10.7IFNG, SELE, TNF
44myopathy-growth delay-intellectual disability-hypospadias syndrome10.7HLA-DPB1, TNF
45pulmonary systemic sclerosis10.7CRP, IFNG, TNF
46neonatal period electroclinical syndrome10.7CRP, ELANE, MPO, TNF
47kidney angiomyolipoma10.7CD8A, MPO, TNF
48hemorrhagic fever with renal syndrome10.7CRP, IFNG, TNF
49pulmonary disease, chronic obstructive10.7ELANE, ELN, SERPINA1
50deafness, autosomal recessive 6210.7ELANE, IFNG, TNF

Comorbidity relations with Wegener Granulomatosis via Phenotypic Disease Network (PDN):


Deficiency AnemiaAcute Kidney Failure
Chronic Kidney FailureNeutropenia
Respiratory Failure

Graphical network of the top 20 diseases related to Wegener Granulomatosis:



Diseases related to wegener granulomatosis

Symptoms for Wegener Granulomatosis

About this section


Clinical features from OMIM:

608710

Human phenotypes related to Wegener Granulomatosis:

 63 53 (show all 78)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the oral cavity63 53 hallmark (90%) Very frequent (99-80%) HP:0000163
2 sinusitis63 53 hallmark (90%) Very frequent (99-80%) HP:0000246
3 epistaxis63 53 hallmark (90%) Very frequent (99-80%) HP:0000421
4 hematuria63 53 hallmark (90%) Very frequent (99-80%) HP:0000790
5 weight loss63 53 hallmark (90%) Very frequent (99-80%) HP:0001824
6 recurrent respiratory infections63 53 hallmark (90%) Very frequent (99-80%) HP:0002205
7 vasculitis63 53 hallmark (90%) Very frequent (99-80%) HP:0002633
8 cerebral ischemia63 53 hallmark (90%) Very frequent (99-80%) HP:0002637
9 arthralgia63 53 hallmark (90%) Very frequent (99-80%) HP:0002829
10 autoimmunity63 53 hallmark (90%) Very frequent (99-80%) HP:0002960
11 paresthesia63 hallmark (90%) HP:0003401
12 abnormality of temperature regulation63 hallmark (90%) HP:0004370
13 glomerulopathy63 53 hallmark (90%) Very frequent (99-80%) HP:0100820
14 proteinuria63 53 typical (50%) Frequent (79-30%) HP:0000093
15 abnormality of the hypothalamus-pituitary axis63 53 typical (50%) Frequent (79-30%) HP:0000864
16 skin rash63 53 typical (50%) Frequent (79-30%) HP:0000988
17 polyneuropathy63 typical (50%) HP:0001271
18 nausea and vomiting63 53 typical (50%) Frequent (79-30%) HP:0002017
19 abdominal pain63 53 typical (50%) Frequent (79-30%) HP:0002027
20 respiratory insufficiency63 53 typical (50%) Frequent (79-30%) HP:0002093
21 hemoptysis63 53 typical (50%) Frequent (79-30%) HP:0002105
22 pulmonary infiltrates63 53 typical (50%) Very frequent (99-80%) HP:0002113
23 pulmonary embolism63 typical (50%) HP:0002204
24 pulmonary fibrosis63 53 typical (50%) Frequent (79-30%) HP:0002206
25 chronic obstructive pulmonary disease63 53 typical (50%) Frequent (79-30%) HP:0006510
26 inflammatory abnormality of the eye63 53 typical (50%) Frequent (79-30%) HP:0100533
27 periorbital edema63 53 typical (50%) Frequent (79-30%) HP:0100539
28 chest pain63 53 typical (50%) Frequent (79-30%) HP:0100749
29 prostatitis63 53 occasional (7.5%) Occasional (29-5%) HP:0000024
30 ureteral stenosis63 53 occasional (7.5%) Occasional (29-5%) HP:0000071
31 renal insufficiency63 53 occasional (7.5%) Occasional (29-5%) HP:0000083
32 otitis media63 53 occasional (7.5%) Very frequent (99-80%) HP:0000388
33 sensorineural hearing impairment63 53 occasional (7.5%) Occasional (29-5%) HP:0000407
34 retinopathy63 53 occasional (7.5%) Occasional (29-5%) HP:0000488
35 visual impairment63 53 occasional (7.5%) Occasional (29-5%) HP:0000505
36 proptosis63 53 occasional (7.5%) Occasional (29-5%) HP:0000520
37 hypertension63 53 occasional (7.5%) Occasional (29-5%) HP:0000822
38 diabetes insipidus63 53 occasional (7.5%) Occasional (29-5%) HP:0000873
39 seizures63 53 occasional (7.5%) Occasional (29-5%) HP:0001250
40 meningitis63 53 occasional (7.5%) Occasional (29-5%) HP:0001287
41 coronary artery disease63 occasional (7.5%) HP:0001677
42 abnormality of the pericardium63 occasional (7.5%) HP:0001697
43 pancreatitis63 53 occasional (7.5%) Occasional (29-5%) HP:0001733
44 subcutaneous hemorrhage63 occasional (7.5%) HP:0001933
45 migraine63 occasional (7.5%) HP:0002076
46 restrictive ventilatory defect63 occasional (7.5%) HP:0002091
47 abnormality of the pleura63 occasional (7.5%) HP:0002103
48 gastrointestinal hemorrhage63 53 occasional (7.5%) Occasional (29-5%) HP:0002239
49 myalgia63 53 occasional (7.5%) Occasional (29-5%) HP:0003326
50 hemiplegia/hemiparesis63 occasional (7.5%) HP:0004374
51 thrombophlebitis63 occasional (7.5%) HP:0004418
52 intestinal obstruction63 53 occasional (7.5%) Occasional (29-5%) HP:0005214
53 cranial nerve paralysis63 53 occasional (7.5%) Occasional (29-5%) HP:0006824
54 arrhythmia63 53 occasional (7.5%) Occasional (29-5%) HP:0011675
55 gangrene63 53 occasional (7.5%) Occasional (29-5%) HP:0100758
56 skin ulcer63 53 occasional (7.5%) Occasional (29-5%) HP:0200042
57 granulomatosis63 53 Very frequent (99-80%) HP:0002955
58 hydronephrosis53 Occasional (29-5%)
59 abnormality of the nose53 Very frequent (99-80%)
60 chronic otitis media53 Occasional (29-5%)
61 sensory neuropathy53 Occasional (29-5%)
62 purpura53 Occasional (29-5%)
63 angina pectoris53 Occasional (29-5%)
64 pericarditis53 Occasional (29-5%)
65 fever53 Very frequent (99-80%)
66 restrictive lung disease53 Occasional (29-5%)
67 pleuritis53 Occasional (29-5%)
68 hemiplegia53 Occasional (29-5%)
69 headache53 Occasional (29-5%)
70 elevated erythrocyte sedimentation rate53 Frequent (79-30%)
71 venous thrombosis53 Occasional (29-5%)
72 recurrent intrapulmonary hemorrhage53 Frequent (79-30%)
73 peripheral neuropathy53 Frequent (79-30%)
74 elevated c-reactive protein level53 Frequent (79-30%)
75 fatigue53 Very frequent (99-80%)
76 increased inflammatory response53 Frequent (79-30%)
77 cough53 Frequent (79-30%)
78 papule53 Frequent (79-30%)

UMLS symptoms related to Wegener Granulomatosis:


chest pain, coughing, snoring, vasculitic rash

Drugs & Therapeutics for Wegener Granulomatosis

About this section

Drugs for Wegener Granulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 106)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
MethotrexateapprovedPhase 4, Phase 3, Phase 2, Phase 115181959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
2
Mycophenolate mofetilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1939128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
3
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
4
Prednisoneapproved, vet_approvedPhase 4, Phase 2, Phase 3135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
5
alemtuzumabapproved, investigationalPhase 4303216503-57-0
Synonyms:
Campath
 
MabCampath
alemtuzumab
6
rituximabapprovedPhase 4, Phase 2, Phase 3, Phase 11654174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
7
Prednisoloneapproved, vet_approvedPhase 4, Phase 2, Phase 3115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
8
Mycophenolic acidapprovedPhase 4, Phase 3, Phase 2, Phase 193924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
9
AzathioprineapprovedPhase 4, Phase 3, Phase 2165446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
10
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 2, Phase 3115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
11
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
12Dermatologic AgentsPhase 4, Phase 3, Phase 25674
13Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 3, Phase 110355
14Autonomic AgentsPhase 4, Phase 2, Phase 39774
15Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 35407
16Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 24474
17Gastrointestinal AgentsPhase 4, Phase 2, Phase 3, Phase 18109
18Protective AgentsPhase 4, Phase 2, Phase 37190
19Vitamin B ComplexPhase 4, Phase 3, Phase 24229
20Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 3, Phase 122776
21Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 24855
22Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 110627
23Neuroprotective AgentsPhase 4, Phase 2, Phase 31672
24Folic Acid AntagonistsPhase 4, Phase 3, Phase 22200
25AntiemeticsPhase 4, Phase 2, Phase 33888
26Methylprednisolone HemisuccinatePhase 4, Phase 2, Phase 31153
27Prednisolone acetatePhase 4, Phase 2, Phase 31153
28Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
29Methylprednisolone acetatePhase 4, Phase 2, Phase 31153
30Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 312767
31glucocorticoidsPhase 4, Phase 2, Phase 34920
32Hormone AntagonistsPhase 4, Phase 2, Phase 312778
33HormonesPhase 4, Phase 2, Phase 3, Phase 113979
34Prednisolone phosphatePhase 4, Phase 2, Phase 31153
35Prednisolone hemisuccinatePhase 4, Phase 2, Phase 31153
36ImmunoglobulinsPhase 4, Phase 2, Phase 3, Phase 16045
37Alkylating AgentsPhase 4, Phase 3, Phase 24694
38Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
39Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17171
40Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 112770
41AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 111774
42AntibodiesPhase 4, Phase 2, Phase 3, Phase 16045
43Antibodies, Antineutrophil CytoplasmicPhase 4, Phase 3, Phase 211
44Tin FluoridesPhase 4246
45Vitamin B9NutraceuticalPhase 4, Phase 3, Phase 24279
46FolateNutraceuticalPhase 4, Phase 3, Phase 24279
47Folinic AcidNutraceuticalPhase 4, Phase 3, Phase 23150
48Omega 3 Fatty AcidNutraceuticalPhase 4969
49
AlendronateapprovedPhase 3160121268-17-5, 66376-36-12088
Synonyms:
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-hydroxybutylidene)bisphosphonic acid
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
4-amino-1-hydroxybutane-1,1-diphosphonic acid
66376-36-1
ABDP
AC1L1CW3
AKOS001015793
ALENDRONATE SODIUM
ALENDRONIC ACID
Acide Alendronique
Acide Alendronique [INN-French]
Acide alendronique
Acide alendronique [INN-French]
Acido Alendronico
Acido Alendronico [INN-Spanish]
Acido alendronico
Acido alendronico [INN-Spanish]
Acidum Alendronicum
Acidum Alendronicum [INN-Latin]
Acidum alendronicum
Acidum alendronicum [INN-Latin]
Adronat
 
Alendronate
Alendronate Sodium
Alendronate sodium hydrate
Alendronic acid
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Arendal
BIDD:GT0180
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
alendronate
bisphosphonate, 65
50
AbataceptapprovedPhase 3, Phase 1, Phase 2192332348-12-610237
Synonyms:
CTLA4-Ig
 
CTLA4-IgG4m
CTLA4Ig
CTLA4IgG4m

Interventional clinical trials:

(show top 50)    (show all 110)
idNameStatusNCT IDPhase
1Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated VasculitisUnknown statusNCT02169219Phase 4
2Alemtuzumab for ANCA Associated Refractory VasculitisUnknown statusNCT01405807Phase 4
3Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated VasculitisUnknown statusNCT00128895Phase 4
4Treatment of Necrotizing Vasculitides for Patients Older Than 65 YearsCompletedNCT00307671Phase 4
5A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic PolyangitisRecruitingNCT02115997Phase 4
6Low-dose Glucocorticoid Vasculitis Induction StudyRecruitingNCT02198248Phase 4
7Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab DosingRecruitingNCT02749292Phase 4
8Rituximab for the Otolaryngologic Manifestations of Granulomatosis With PolyangiitisNot yet recruitingNCT02626845Phase 4
9Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")TerminatedNCT00747461Phase 4
10Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein LevelsTerminatedNCT00578578Phase 4
11Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)Unknown statusNCT00103792Phase 3
12WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated VasculitidesUnknown statusNCT00349674Phase 3
13Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaUnknown statusNCT00003338Phase 2, Phase 3
14Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's LymphomaUnknown statusNCT00003337Phase 3
15Etanercept for Wegener's GranulomatosisCompletedNCT00005007Phase 2, Phase 3
16A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With PolyangiitisCompletedNCT02020889Phase 3
17Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)CompletedNCT00647166Phase 3
18Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic PolyangiitisCompletedNCT00104299Phase 2, Phase 3
19Efficacy Study of Two Treatments in the Remission of VasculitisCompletedNCT00748644Phase 3
20Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated VasculitidesCompletedNCT00430105Phase 2, Phase 3
21Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.CompletedNCT00138983Phase 3
22Rituximab in Eosinophilic Granulomatosis With PolyangiitisRecruitingNCT02807103Phase 3
23Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)RecruitingNCT02108860Phase 3
24The Assessment of Prednisone In Remission Trial - Centers of Excellence ApproachRecruitingNCT01940094Phase 3
25Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell TumoursRecruitingNCT02582697Phase 3
26Belimumab in Remission of VASculitisActive, not recruitingNCT01663623Phase 3
27Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated VasculitisActive, not recruitingNCT00987389Phase 3
28Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated VasculitisActive, not recruitingNCT01731561Phase 3
29Rituximab Vasculitis Maintenance StudyActive, not recruitingNCT01697267Phase 3
30Comparison Between a Long Term and a Conventional Maintenance Treatment With RituximabActive, not recruitingNCT02433522Phase 3
31Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)Not yet recruitingNCT02836496Phase 3
32Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's GranulomatosisTerminatedNCT01446211Phase 3
33Intravenous Immunoglobulin After Relapse in VasculitisTerminatedNCT00307658Phase 3
34Plasma Exchange for Renal VasculitisTerminatedNCT01408836Phase 2, Phase 3
35IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic VasculitisTerminatedNCT00307645Phase 3
36Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic CancerTerminatedNCT01956812Phase 3
37Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing VasculitidesUnknown statusNCT00751517Phase 2
38Improving Outcomes Following Limb Loss: PALS PlusUnknown statusNCT00447655Phase 1, Phase 2
39Phase II Study on Gusperimus in Patients With Refractory Wegener's GranulomatosisCompletedNCT00530075Phase 2
40Daclizumab to Treat Wegener's GranulomatosisCompletedNCT00040248Phase 2
41Abatacept in Treating Adults With Mild Relapsing Wegener's GranulomatosisCompletedNCT00468208Phase 1, Phase 2
42Etanercept to Treat Wegener's GranulomatosisCompletedNCT00001901Phase 2
43Treatment of Wegener's Granulomatosis With CyclophosphamideCompletedNCT00001155Phase 2
44Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis SyndromesCompletedNCT00004567Phase 2
45Steroids and Methotrexate to Treat Systemic VasculitisCompletedNCT00001256Phase 2
46Anti-Cytokine Therapy for VasculitisCompletedNCT00753103Phase 2
47Safety and Efficacy Study of 90Y-hPAM4 at Different DosesCompletedNCT00597129Phase 1, Phase 2
48Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's LymphomaCompletedNCT00285428Phase 1, Phase 2
49Safety Study of NHL With 90Y-hLL2 IgGCompletedNCT00421395Phase 1, Phase 2
50Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgGCompletedNCT00061425Phase 1, Phase 2

Search NIH Clinical Center for Wegener Granulomatosis

Inferred drug relations via UMLS67/NDF-RT45:


Cochrane evidence based reviews: granulomatosis with polyangiitis

Genetic Tests for Wegener Granulomatosis

About this section

Anatomical Context for Wegener Granulomatosis

About this section

MalaCards organs/tissues related to Wegener Granulomatosis:

35
Lung, Kidney, Skin, Trachea, Neutrophil, Monocytes, Testes

FMA organs/tissues related to Wegener Granulomatosis:

17
Lung, Kidney, Skin

Animal Models for Wegener Granulomatosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Wegener Granulomatosis:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053859.6CCR5, CRP, CTLA4, IFNG, MPO, PTPN22
2MP:00053709.0CCR5, CTLA4, CTSG, IFNG, PTPN22, RXRB
3MP:00053978.7CCR5, CD177, CD80, CD8A, CTLA4, CTSG
4MP:00053878.5CCR5, CD177, CD80, CD8A, CRP, CTLA4

Publications for Wegener Granulomatosis

About this section

Articles related to Wegener Granulomatosis:

(show top 50)    (show all 57)
idTitleAuthorsYear
1
Management Scheme for Cerebral Wegener Granulomatosis: An Unusual Pseudotumoral Skull Base Pathology. (27671887)
2016
2
Tracheal Stenosis Because of Wegener Granulomatosis Misdiagnosed as Asthma. (27075424)
2016
3
Orbital involvement as the initial presentation of Wegener granulomatosis in a 9-year-old girl: MR imaging findings. (27425807)
2016
4
Monoclonal B-cell Lymphocytosis in a Patient with Wegener Granulomatosis: A Case Report and Update on 2016 World Health Organization Classification. (27625103)
2016
5
Malignant Pyoderma Associated with Granulomatosis with Polyangiitis (Wegener Granulomatosis) as a Unique Indication for Facial Vascularized Composite Allotransplantation: Part I. (27219252)
2016
6
Image Gallery: Symmetrical necrosis of the breast as an inaugural manifestation of granulomatosis with polyangiitis (Wegener granulomatosis). (27790680)
2016
7
Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma. (27521731)
2016
8
Total nasal skeletal reconstruction disfigured by granulomatosis with polyangitis (wegener granulomatosis). (25750847)
2015
9
Nasal mucosa narrow band imaging in granulomatosis with polyangiitis (Wegener granulomatosis): A preliminary study. (25781561)
2015
10
Renal cell carcinoma metastatic to the orbit in a patient with Wegener granulomatosis. (25295684)
2015
11
Airway Surgery in Tracheostomised Patients with Wegener Granulomatosis Leading to Subglottic Stenosis. (27366530)
2015
12
Wegener granulomatosis with supraglottic involvement. (26433716)
2015
13
Wegener Granulomatosis: Otologic Manifestation as First Symptom. (26157503)
2015
14
Wegener granulomatosis as possible cause of vertigo: case report and review. (26513951)
2015
15
Ultrasonographic imaging of the peripheral nerves in a Wegener granulomatosis patient with multiple mononeuropathies. (24811470)
2014
16
Changes in sinonasal mucosa in Wegener granulomatosis. (24616132)
2014
17
Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings. (25076302)
2014
18
An unusual orbital localization of wegener granulomatosis detected by 18F-FDG PET/CT. (23856831)
2014
19
Coexistent pulmonary granulomatosis with polyangiitis (Wegener granulomatosis) and Crohn disease. (24525506)
2014
20
Limited-Form Wegener Granulomatosis Case: Anaesthetic Approach and Literature Review. (27366454)
2014
21
Long-term Outcome of Airway Stenosis in Granulomatosis With Polyangiitis (Wegener Granulomatosis): An Observational Study. (25321076)
2014
22
Wegener granulomatosis as an uncommon cause of panhypopituitarism in childhood. (23729544)
2013
23
Clinical features and outcomes of 37 Argentinean patients with severe granulomatosis with polyangiitis (wegener granulomatosis). (23364664)
2013
24
Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis). (23385856)
2013
25
Pathology quiz case 3: Wegener granulomatosis. (23681045)
2013
26
Pyoderma gangrenosum and Wegener granulomatosis-like syndrome induced by cocaine. (24252079)
2013
27
Wegener granulomatosis--rare case presentation. (23777030)
2012
28
Palpable purpura, gingival ulcerations and joint pain in a 24-year-old man. Granulomatosis with polyangiitis (formerly known as Wegener granulomatosis). (22726723)
2012
29
Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment. (21674414)
2011
30
Early extracorporeal life support as rescue for Wegener granulomatosis with diffuse alveolar hemorrhage and acute respiratory distress syndrome: a case report and literature review. (22158275)
2011
31
Cardiac involvement in granulomatosis with polyangiitis (Wegener granulomatosis). (21947937)
2011
32
Granulomatous choroiditis in Wegener granulomatosis. (21482884)
2011
33
Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement. (21674413)
2011
34
EULAR/PRINTO/PRES criteria for Henoch-SchAPnlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. (20413568)
2010
35
Isolated blue toe syndrome as the initial sign of Wegener granulomatosis. (20609674)
2010
36
Wegener granulomatosis presenting as epididymitis. (19376569)
2009
37
Labyrinthitis related to Wegener granulomatosis: magnetic resonance imaging findings. (18097336)
2008
38
A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. (18854317)
2008
39
On the Wegener granulomatosis associated region on chromosome 6p21.3. (16526951)
2006
40
Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. (15758841)
2005
41
Transalar encephalocele associated with Wegener granulomatosis and meningeal enhancement: case report. (16091548)
2005
42
Association study with Wegener granulomatosis of the human phospholipase Cgamma2 gene. (15703080)
2005
43
Spontaneous pneumothorax in Wegener granulomatosis. (16236988)
2005
44
Association study of Wegener granulomatosis and the functionally relevant A645G polymorphism in the bactericidal/permeability increasing protein (BPI) gene. (15686586)
2005
45
Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis. (12418444)
2002
46
Chronic cicatrizing conjunctivitis in a patient with ocular cicatricial pemphigoid and fatal Wegener granulomatosis. (11730661)
2001
47
Wegener granulomatosis and microscopic polyangiitis. Diagnostic and clinical results in 54 patients with long-term follow-up]. (11190761)
2000
48
Structural analysis of human antibodies to proteinase 3 from patients with Wegener granulomatosis. (9218586)
1997
49
Tracheoesophageal fistula due to Wegener granulomatosis. (7769627)
1995
50
Chest radiograph in lymphomatoid granulomatosis: comparison with Wegener granulomatosis. (6606968)
1984

Variations for Wegener Granulomatosis

About this section

Copy number variations for Wegener Granulomatosis from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1216291159859611159867782Copy numberFCGR3BWegener''s granulomatosis
2217951161592989161601158Copy numberFCGR3BWegener''s granulomatosis

Expression for genes affiliated with Wegener Granulomatosis

About this section
Search GEO for disease gene expression data for Wegener Granulomatosis.

Pathways for genes affiliated with Wegener Granulomatosis

About this section

Pathways related to Wegener Granulomatosis according to GeneCards Suite gene sharing:

(show all 17)
idSuper pathwaysScoreTop Affiliating Genes
110.0ELANE, MPO, PRTN3
210.0ELANE, MPO, TNF
310.0ELANE, ELN, SELE
4
Show member pathways
9.9CTLA4, IFNG, TNF
59.9IFNG, SELE, TNF
69.9IFNG, SELE, TNF
7
Show member pathways
9.8CD8A, IFNG, TNF
89.8CD8A, IFNG, TNF
99.8CD8A, IFNG, TNF
109.7CD80, CD8A, CTLA4, PTPN22
11
Show member pathways
9.7CCR5, HLA-DPB1, IFNG, TNF
129.6CD80, CD8A, CTLA4, HLA-DPB1, SELE
139.5CD80, CTLA4, HLA-DPB1, IFNG, TNF
14
Show member pathways
9.5CCR5, CD8A, CTLA4, IFNG, TNF
159.4CD80, CD8A, IFNG, MPO, TNF
169.4CD8A, CTLA4, IFNG, MPO, PTPN22, TNF
17
Show member pathways
9.3CD80, CD8A, CTLA4, HLA-DPB1, IFNG, TNF

GO Terms for genes affiliated with Wegener Granulomatosis

About this section

Cellular components related to Wegener Granulomatosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein complex involved in cell adhesionGO:009863610.7CD80, CTLA4
2secretory granuleGO:003014110.6CTSG, ELANE, MPO
3external side of plasma membraneGO:00098979.4CCR5, CD80, CD8A, CTLA4, IFNG, TNF
4extracellular regionGO:00055768.9CD8A, CRP, CTSG, ELANE, ELN, IFNG
5cell surfaceGO:00099868.9CCR5, CD80, CD8A, CTSG, ELANE, HLA-DPB1
6extracellular spaceGO:00056158.7BPI, CRP, CTSG, ELANE, IFNG, MPO

Biological processes related to Wegener Granulomatosis according to GeneCards Suite gene sharing:

(show all 20)
idNameGO IDScoreTop Affiliating Genes
1response to yeastGO:000187810.8ELANE, MPO
2leukocyte tethering or rollingGO:005090110.8SELE, TNF
3positive regulation of interleukin-8 biosynthetic processGO:004541610.8ELANE, TNF
4positive regulation of vitamin D biosynthetic processGO:006055710.7IFNG, TNF
5positive regulation of calcidiol 1-monooxygenase activityGO:006055910.7IFNG, TNF
6leukocyte migration involved in inflammatory responseGO:000252310.7ELANE, SELE
7positive regulation of chemokine biosynthetic processGO:004508010.7IFNG, TNF
8positive regulation of immune responseGO:005077810.7CTSG, ELANE
9negative regulation of lipid storageGO:001088810.6CRP, TNF
10extracellular matrix disassemblyGO:002261710.4CTSG, ELANE, ELN
11defense response to fungusGO:005083210.2CTSG, ELANE, MPO
12cellular response to lipopolysaccharideGO:007122210.1CCR5, CD80, IFNG, TNF
13negative regulation of growth of symbiont in hostGO:004413010.1CTSG, ELANE, IFNG, MPO, TNF
14defense response to Gram-positive bacteriumGO:00508309.9CRP, CTSG, TNF
15positive regulation of T cell proliferationGO:00421029.9CD80, HLA-DPB1, IFNG
16defense response to bacteriumGO:00427429.9BPI, ELANE, IFNG, TNF
17response to lipopolysaccharideGO:00324969.9CTSG, ELANE, MPO, PTPN22, SELE
18leukocyte migrationGO:00509009.8CD177, ELANE, SELE, TNF
19T cell costimulationGO:00312959.7CD80, CTLA4, HLA-DPB1
20immune responseGO:00069559.5BPI, CCR5, CD8A, CTLA4, CTSG

Molecular functions related to Wegener Granulomatosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protease bindingGO:000202010.0ELANE, SERPINA1, TNF
2coreceptor activityGO:00150269.5CCR5, CD80, CD8A

Sources for Wegener Granulomatosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet